Asthma Drugs Market Report 2025

The asthma drugs market size has grown steadily in recent years. It will grow from $23.96 billion in 2024 to $24.93 billion in 2025 at a compound annual growth rate (CAGR) of 4%. The growth in the historic period can be attributed to environmental factors, increased respiratory disorders, lifestyle changes, healthcare infrastructure development.

The asthma drugs market size is expected to see strong growth in the next few years. It will grow to $31.38 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rising air pollution levels, growing aging population, increasing healthcare awareness, personalized medicine trends, biopharmaceutical innovations. Major trends in the forecast period include small molecule therapies, home-based asthma care, biomarker-guided therapies, therapeutic advances in severe asthma, collaborations for asthma research.

The forecast of 5.9% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. allergy clinics by driving up costs of inhaled corticosteroid and long-acting beta2-agonist combination inhalers imported from Spain and Switzerland, exacerbating severe asthma management expenses and increasing respiratory care burdens for chronic patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of asthma is anticipated to drive growth in the asthma drug market. Asthma is a chronic condition characterized by inflammation and swelling of the airways, which leads to their narrowing and restricts airflow from the nose and mouth to the lungs. Due to the increasing number of asthma cases, there has been a significant rise in the development of new medications to address asthmatic disorders. For example, in April 2024, Asthma + Lung UK, a charity based in England that assists individuals with lung conditions, reported that asthma-related deaths in England rose from 1,146 in 2021 to 1,236 in 2022. This increase highlights a troubling upward trend in fatalities linked to the condition over the past year.

The increasing prevalence of respiratory diseases is set to enhance the asthma drug market. Respiratory diseases are medical conditions that impact the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. The rise in respiratory diseases fuels the demand for asthma medications to manage and relieve symptoms associated with these conditions. As respiratory diseases become more common, particularly those like asthma that involve chronic inflammation and airway constriction, the need for effective therapeutic solutions grows. For example, in September 2024, the American Lung Association, a professional organization based in the U.S., reported that over 35 million people in the U.S. were living with a chronic lung condition, such as asthma or COPD, in 2023. Approximately 11.7 million adults, or 4.6% of the population, have been diagnosed with COPD, which encompasses chronic bronchitis and emphysema. Consequently, the rising prevalence of respiratory diseases will propel the asthma drug market forward.

Innovative product development stands as a significant trend gaining traction within the asthma drug market. Major players within this sector are strategically focused on creating novel solutions to maintain their market position. An illustration of this trend is evident in the collaboration between Amgen, a US-based biopharmaceutical company, and AstraZeneca, a UK-based biopharmaceutical company, resulting in the FDA approval of Tezpire, an injectable drug engineered to alleviate asthma symptoms. Tezpire's mechanism of action involves curbing inflammation linked to asthma attacks, exhibiting potential benefits for individuals with severe asthma, including those previously lacking effective treatment options. As the first biologic to consistently reduce asthma-related exacerbations in Phase 2 and 3 clinical trials, the approval of Tezpire promises greater therapeutic advantages, aligning with the escalating instances of asthma cases.

Major companies in the asthma drugs market are prioritizing innovations like fixed-dose combination (FDC) drugs to improve treatment effectiveness and patient adherence. An FDC drug is a medication that combines two or more active ingredients into a single dosage form, such as a tablet, capsule, or inhaler. For example, in June 2022, Glenmark Pharmaceuticals, a pharmaceutical company based in India, launched Indamet, a fixed-dose combination drug aimed at patients with uncontrolled asthma. This innovative treatment merges Indacaterol, a long-acting beta-agonist, with Mometasone Furoate, an inhaled corticosteroid, and is available in various strengths, including Indacaterol 150 mcg with Mometasone at 80 mcg, 160 mcg, and 320 mcg. Designed for once-daily use, Indamet is intended for adults and adolescents aged 12 years and older.

In March 2022, Sandoz, a German pharmaceutical company, successfully acquired Coalesce Product Development Limited for an undisclosed sum. This strategic acquisition aligns with Sandoz's goal of expanding its respiratory division's portfolio and solidifying its global leadership in respiratory products. Through this transaction, Sandoz gains valuable assets and enhanced capabilities in medical and drug-device development, particularly in the respiratory and complex generics markets. The acquisition positions Sandoz to better serve patients with respiratory diseases, including asthma and COPD, by offering affordable and high-quality drug-device combination products, such as inhalers. Coalesce Product Development Limited, based in the UK, is a company specializing in the development of drug delivery devices, boasting a diverse portfolio that includes pressurized metered-dose inhalers, breath-actuated inhalers, pre-metered dry powder inhalers, and more.

Major companies operating in the asthma drugs market include Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC., GlaxoSmithKline PLC., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Cipla Limited, Chiesi Farmaceutici S.p.A., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals, Mundipharma International Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Alembic Pharmaceuticals Limited, Sunovion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Ltd, Innoviva Inc., Vectura Group, Circassia Group PLC, Pulmatrix Inc., Atopix Therapeutics Limited.

North America was the largest region in the asthma drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the asthma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The asthma drugs market research report is one of a series of new reports that provides asthma drugs market statistics, including the asthma drugs industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed asthma drugs market segments, asthma drugs market trends, and opportunities, and any further data you may need to thrive in the asthma drugs industry. This asthma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Asthma is a chronic respiratory condition characterized by inflammation and constriction of the airways, resulting in difficulty breathing. This condition is triggered by factors such as allergens, leading to airway narrowing and excess mucus production. Asthma drugs play a vital role in managing symptoms associated with asthma.

Asthma can be categorized into allergic and non-allergic types. Allergic asthma involves airway constriction triggered by exposure to allergens, leading to respiratory difficulties. Various triggers for asthma include adult-onset asthma, child-onset asthma, cough-induced asthma, exercise-induced asthma, occupational asthma, nocturnal asthma, and steroid-resistant asthma. Asthma drugs are classified into bronchodilators, monoclonal antibodies, anti-inflammatory drugs, and combination drugs, catering to the needs of asthma and COPD patients.

The asthma drugs market consists of sales of drugs such as bronchodilators (beta-2 agonists), monoclonal antibodies (omalizumab, mepolizumab), and anti-inflammatory drugs (budesonide, ciclesonide), used for the treatment of asthma in patients of all ages. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.